Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katherine Boyd-Cordova

Physician Assistant, Surgical Anaheim, CA Physician Assistant

NPI 1023591450 CMS profile 10807783

9918 Katella Ave Ste A-C, Anaheim, CA 92804

Open in the dashboard

General payments

$2,602

36 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine Boyd-Cordova of Anaheim, CA is reported in the CMS Open Payments database as having received $2,602 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,405 24
2024 General $70 3
2023 General $197 5
2022 General $96 2
2021 General $834 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Boyd-Cordova
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Katherine Boyd-Cordova were reported at $1,405. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Katherine Boyd-Cordova Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $834 $111 $36–$285 $132
2022 $96 $126 $44–$350 $149
2023 $197 $137 $47–$355 $160
2024 $70 $146 $49–$384 $164
2025 $1,405 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teleflex LLC $1,142 10 payments
  2. Biohaven Pharmaceuticals, Inc. $834 2 payments
  3. AbbVie, Inc. $140 6 payments
  4. Astellas Pharma US Inc $112 2 payments
  5. Medtronic, Inc. $111 3 payments
  6. Sumitomo Pharma America, Inc. $81 4 payments
  7. Immunitybio, Inc. $42 2 payments
  8. Novo Nordisk Inc $40 2 payments
  9. Myriad Genetic Laboratories, Inc. $38 2 payments
  10. Merz North America, Inc. $32 1 payment
  11. Other $30 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,200 32 payments
  2. Consulting Fee $800 1 payment
  3. Travel and Lodging $521 2 payments
  4. Education $80 1 payment
Products named General payments · program years 2021–2025
  1. BARRIGEL $950 6 payments
  2. NURTEC ODT $834 2 payments
  3. UROLIFT Interventional Urology $143 2 payments
  4. BOTOX $140 6 payments
  5. INTERSTIM $111 3 payments
  6. GEMTESA $81 4 payments
  7. UROLIFT Interventional Urology $49 2 payments
  8. ANKTIVA $42 2 payments
  9. PROLARIS $38 2 payments
  10. Xeomin $32 1 payment
  11. Other $86 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

507

Median for Physician Assistant: 241

Drug cost

$59,409

Median for Physician Assistant: $4,110

Branded share of claims

52.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 41 $32,688
Myrbetriq Mirabegron Brand 17 $12,366
Estradiol Generic 98 $7,393
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 50 $2,513
Tamsulosin Hcl Generic 46 $1,120
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 78 $854
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 20 $675
Finasteride Generic 32 $491
Cephalexin Generic 18 $368
Cefdinir Generic 15 $310

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$24,936

Of which drugs: $131

Medicare patients

195

Average age 78

Services billed

1,466

158 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Osteoporosis 28%
Ischemic heart disease 27%
Chronic kidney disease 27%
Diabetes 26%
Cancer 22%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, heparin sodium, per 1000 units J1644 Office 11 626 $131

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $38
$38 41 —
Veozah
  • Astellas Pharma US Inc $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record